Generate Biomedicines Inc GENB
$16.12 $0.13 (0.81%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
GENB Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Generate Biomedicines Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Generate Biomedicines Inc. Stock Analysis GENB
United States Health Care Mid Cap Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company is headquartered in Somerville, Massachusetts and currently employs 312 full-time employees. The company went IPO on 2026-02-27. The firm is engaged in the field of generative biology using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its Generate Platform integrates generative and predictive models that learn design principles from proprietary data and graph neural networks, among other architectures. Its lead product candidate, GB-0895, is an investigational long-acting anti-TSLP monoclonal antibody in development for severe asthma. Its other product candidates include GB-4362, a systemically administered monoclonal antibody designed to neutralize free monomethyl auristatin E (MMAE) as an adjunctive therapy to antibody-drug conjugate (ADC) molecules with an MMAE payload, as well as GB-5267, an armored, MUC16-directed CAR-T cell therapy candidate.
Generate Biomedicines Inc (GENB) Chart
Financial Metrics & Statements of Generate Biomedicines Inc (GENB)
FAQ's for Generate Biomedicines Inc (GENB)
- As of August 2026, Generate Biomedicines Inc GENB is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Generate Biomedicines Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Generate Biomedicines Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Generate Biomedicines Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Generate Biomedicines Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Generate Biomedicines Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Generate Biomedicines Inc (GENB)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
